Leukemia Therapeutics Market By Type, By Drug Class, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

List of Tables

The global leukemia therapeutics market valued for $7,818.63 million in 2021 and is estimated to reach $14,162.48 million by 2031, exhibiting a CAGR of 6.1% from 2022 to 2031.

Leukemia is a type of blood cancer that affects the blood and bone marrow. It is characterized by the uncontrolled production of abnormal white blood cells, which can interfere with the normal functioning of the blood and the immune system. There are several types of leukemia, including acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). The rare types of leukemia include chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML). Treatment for these rare forms of leukemia may involve a combination of chemotherapy, and others treatment depending on the type and stage of the leukemia and the overall health of the patient. Symptoms of leukemia can include fatigue, weakness, frequent infections, and easy bruising or bleeding.

A number of commercially available drugs have been developed to treat leukemia and are driving the demand for leukemia therapeutics. Some of the most commonly used drugs include Gleevec, Bosulif, Sprycel, Iculsig, and others. These drugs have shown significant efficacy in the treatment of leukemia and have become the standard of care for many patients. In addition, the development of new and improved drugs for the treatment of leukemia drives the demand for leukemia therapeutics.

The leukemia therapeutics market is experiencing growth owing to rise in cases of leukemia and the number of bone marrow biopsies across the world. In addition, the increase in investment in the R&D activities for leukemia and rise in awareness of the targeted therapies among the population further drive the growth of the leukemia therapeutics market. The introduction of new drugs has led to improved survival rates for patients with leukemia, giving them a better chance of beating the disease which further supports the market growth.

In contrast, the stringent regulatory approvals for the leukemia therapeutics and the side effect of the drugs used in the leukemia treatment impedes the growth of the market. For instance, Onureg (azacitidine) causes dizziness, nausea, vomiting, fatigue, anemia, and low platelet count in patients with leukemia. In addition, patent expiry of the drugs used in the treatment of leukemia and the higher costs involved in the therapies limit the growth of the global leukemia therapeutics market. Moreover, the rise in number of clinical trials for leukemia and new product approvals are anticipated to create newer opportunities in the emerging as well as the developed markets. For instance, in December 2020, Amgen announced the U.S. Food and Drug Administration (FDA) has approved RIABNI (rituximab-arrx), a biosimilar to Rituxan (rituximab), for the treatment of adult patients with chronic lymphocytic leukemia (CLL).

The global leukemia therapeutics market is segmented into type, drug class, distribution channel, and region. By type, the market is categorized into acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and others. On the basis of drug class, the market is segregated into chemotherapy, and targeted & immunotherapy. By distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global leukemia therapeutics market are: AbbVie Inc. Amgen Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Lupin, Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global leukemia therapeutics market analysis from 2021 to 2031 to identify the prevailing global leukemia therapeutics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the global leukemia therapeutics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global leukemia therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

Acute Lymphocytic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Others

By Drug Class

Chemotherapy
Targeted Therapy and Immunotherapy

By Distribution channel

Hospital Pharmacies
Drug Store and Retail Pharmacies
Online Providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players

Amgen Inc.
Bristol-Myers Squibb Company
Lupin
Sanofi
Gilead Sciences, Inc.
Takeda Pharmaceutical Company Limited
Abbvie Inc
Pfizer Inc.
Teva Pharmaceutical Industries Limited
Novartis AG

Product Code: A01128

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in incidences of leukemia
  - 3.4.1.2. Rise in product approval
- 3.4.2. Restraints
  - 3.4.2.1. Side-effects and adverse reactions of leukemia therapeutics
  - 3.4.2.2. High cost of leukemia therapeutics
- 3.4.3. Opportunities
  - 3.4.3.1. High growth potential in developing economies
  - 3.4.3.2. Increase in R&D activities
3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: LEUKEMIA THERAPEUTICS MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Acute Lymphocytic Leukemia
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Acute Myeloid Leukemia
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Chronic Lymphocytic Leukemia
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Chronic Myeloid Leukemia
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
4.6. Others
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country

CHAPTER 5: LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Chemotherapy
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Targeted Therapy and Immunotherapy
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Drug Store and Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online Providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: LEUKEMIA THERAPEUTICS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Drug Class
- 7.2.4. Market size and forecast, by Distribution channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Type
  - 7.2.5.1.3. Market size and forecast, by Drug Class
  - 7.2.5.1.4. Market size and forecast, by Distribution channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Type
  - 7.2.5.2.3. Market size and forecast, by Drug Class
  - 7.2.5.2.4. Market size and forecast, by Distribution channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Type
  - 7.2.5.3.3. Market size and forecast, by Drug Class
  - 7.2.5.3.4. Market size and forecast, by Distribution channel
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Drug Class
- 7.3.4. Market size and forecast, by Distribution channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Type
  - 7.3.5.1.3. Market size and forecast, by Drug Class
  - 7.3.5.1.4. Market size and forecast, by Distribution channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Type
  - 7.3.5.2.3. Market size and forecast, by Drug Class
  - 7.3.5.2.4. Market size and forecast, by Distribution channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Type
  - 7.3.5.3.3. Market size and forecast, by Drug Class
  - 7.3.5.3.4. Market size and forecast, by Distribution channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Type
  - 7.3.5.4.3. Market size and forecast, by Drug Class
  - 7.3.5.4.4. Market size and forecast, by Distribution channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Type
  - 7.3.5.5.3. Market size and forecast, by Drug Class
  - 7.3.5.5.4. Market size and forecast, by Distribution channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Type
  - 7.3.5.6.3. Market size and forecast, by Drug Class
  - 7.3.5.6.4. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Type
- 7.4.3. Market size and forecast, by Drug Class
- 7.4.4. Market size and forecast, by Distribution channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Type
  - 7.4.5.1.3. Market size and forecast, by Drug Class
  - 7.4.5.1.4. Market size and forecast, by Distribution channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Type
  - 7.4.5.2.3. Market size and forecast, by Drug Class
  - 7.4.5.2.4. Market size and forecast, by Distribution channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Type
  - 7.4.5.3.3. Market size and forecast, by Drug Class
  - 7.4.5.3.4. Market size and forecast, by Distribution channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Type
  - 7.4.5.4.3. Market size and forecast, by Drug Class
  - 7.4.5.4.4. Market size and forecast, by Distribution channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Type
  - 7.4.5.5.3. Market size and forecast, by Drug Class
  - 7.4.5.5.4. Market size and forecast, by Distribution channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Type
  - 7.4.5.6.3. Market size and forecast, by Drug Class
  - 7.4.5.6.4. Market size and forecast, by Distribution channel
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Type
- 7.5.3. Market size and forecast, by Drug Class
- 7.5.4. Market size and forecast, by Distribution channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Type
  - 7.5.5.1.3. Market size and forecast, by Drug Class
  - 7.5.5.1.4. Market size and forecast, by Distribution channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Type
  - 7.5.5.2.3. Market size and forecast, by Drug Class
  - 7.5.5.2.4. Market size and forecast, by Distribution channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Type
  - 7.5.5.3.3. Market size and forecast, by Drug Class
  - 7.5.5.3.4. Market size and forecast, by Distribution channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Type
  - 7.5.5.4.3. Market size and forecast, by Drug Class
  - 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

9.1. Abbvie Inc
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Amgen Inc.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. Pfizer Inc.
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Novartis AG
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
9.5. Gilead Sciences, Inc.
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
9.6. Bristol-Myers Squibb Company
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. Sanofi
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. Teva Pharmaceutical Industries Limited
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. Lupin
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Takeda Pharmaceutical Company Limited
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments